Trials / Completed
CompletedNCT06268847
Efficacy of Marine By-product Hydrolysate on the Reduction of Atopic Dermatitis Symptoms
Evaluation of the Effect of Marine By-product Hydrolysate Supplementation on the Reduction of Atopic Dermatitis Symptoms : a Randomized, Placebo-controlled, Double-blind Study
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 92 (actual)
- Sponsor
- Abyss Ingredients · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This interventional, double-blind, randomized, placebo-controlled study aims to evaluate the effect of a marine by-product hydrolysate supplementation on the reduction of atopic dermatitis symptoms.
Detailed description
The study will be carried out with 108 subjects divided in 3 groups of 36 subjects who will be supplemented with two dosages of the food supplement or a placebo. This study intends to assess objectively and subjectively the efficacy of a food supplement claimed to improve the skin condition related to atopic dermatitis. The objectives of the study consist in the evaluation of the supplementation to improve the skin condition and symptoms on atopic dermatitis (by SCORAD), to reduce the eczema and severity on atopic dermatitis (by SCORAD and Eczema Area and Severity Index), to reduce the inflammatory signs (by Investigator Global Assessment scale), to moisturize and to improve/maintain the skin barrier.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Placebo | The placebo product containing mainly maltodextrin is presented in the same form as the active product, so that people handling the product cannot distinguish between them. The placebo is flavoured in order to have a fishy smell just like the active product. 2 capsules per day for 90 days of placebo. |
| DIETARY_SUPPLEMENT | ACT01 | 2 capsules per day (2 per dose) of 300mg (dose per capsule) for 90 days of study product. |
| DIETARY_SUPPLEMENT | ACT02 | 2 capsules per day (2 per dose) of 300mg (dose per capsule) for 90 days of study product. |
Timeline
- Start date
- 2024-01-09
- Primary completion
- 2024-04-02
- Completion
- 2024-07-03
- First posted
- 2024-02-20
- Last updated
- 2024-08-21
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT06268847. Inclusion in this directory is not an endorsement.